Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who previously received allogeneic hematopoietic cell transplantation due to hematologic malignancy, bone marrow failure syndrome, and other compatible disease.~* Patients who are diagnosed as bronchiolitis obliterans (BO) according to the NIH diagnostic guideline which is suggested as below.~* Patients should be 15 years of age or older, but younger than 75 years.~* Patients should have estimated life expectancy of more than 3 months.~* Patients must have adequate hepatic function (bilirubin less than 3.0 ㎎/㎗, AST and ALT less than three times the upper normal limit).~* Patients must have adequate renal function (creatinine less than 2.0 ㎎/㎗).~Exclusion Criteria:~* Presence of significant active infection~* Presence of uncontrolled bleeding~* Any coexisting major illness or organ failure~* Patients with a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible.~* Nursing women, pregnant women, women of childbearing potential who do not want adequate contraception~* Patients with a diagnosis of prior malignancy unless disease-free for at least 5 years following therapy with curative intent (except curatively treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia)

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): Patient who are diagnosed as bronchiolitis obliterans according to the WHO criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).